Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Boehringer Ingelheim (2)
42 Articles Available
2
2
Can't find what you're looking for? Try our
advanced search
.
Animal Health
Merial, Now Part of Boehringer Ingelheim, Grows Canine Vaccine Portfolio With Introduction of RECOMBITEK® Oral Bordetella
PR-M02-18-NI-038
Contract
Prime Therapeutics and Boehringer Ingelheim Enter Into Outcomes-Based Contract for Jardiance®
PR-M02-18-NI-013
Staffing
Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018
PR-M02-18-NI-012
Drug Development
New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban
PR-M01-18-NI-097
FDA Approval
FDA to Expand the Use of Gilotrif
PAO-M01-18-NI-038
FDA Approval
FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC
PR-M01-18-NI-062
Partnership
Boehringer Ingelheim and Adimab Partner on Antibodies
PAO-M01-18-NI-030
Investment
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
PR-M01-18-NI-010
Oncology
Holiday Program Brings Hope Home to Lung Cancer Patients
PR-M12-17-NI-002
Discovery
Boehringer Ingelheim and HitGen Enter Drug Discovery Collaboration
PAO-M11-17-NI-049
Biosimilars
Boehringer Ingelheim’s Adalimumab Biosimilar Wins First EU Approval
PAO-M11-17-NI-045
Strategic Partnership
Dicerna and Boehringer Ingelheim Ink Deal to Develop Treatments for Chronic Liver Diseases
PAO-M11-17-NI-022
FDA
FDA Grants Priority Review to Gilotrif® For Uncommon EGFR Mutations in Advanced NSCLC
PR-M10-17-NI-002
Clinical Data
Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF
PR-M08-17-NI-012
Biosimilar
Another Biosimilar Gets FDA Nod
PAO-M09-17-NI-011
Growth Strategy
Boehringer Ingelheim Achieves Good Growth in the First Half of 2017
PR-M08-17-NI-004
Capacity Expansion
Boehringer Ingelheim Expands Biologics Manufacturing Capacity in California
PAO-M08-17-NI-007
CDMO
Boehringer Ingelheim Expands its Contract Manufacturing in China
PAO-M05-17-NI-029
«
2
2
.svg)
